VERAXA Biotech Advances Lead BiTAC T-Cell Engager Program with Cell Line Development Partnership

VERAXA Biotech AG (NASDAQ: VRXA) has taken a significant step forward in its lead BiTAC(R) T-cell engager (BiTAC-TCE) program by initiating cell line development, the company announced. The partnership with ATUM, a U.S.-based contract research organization, aims to generate stable clonal cell lines using ATUM's proprietary Leap-In Transposase(R) technology. This collaboration supports the manufacturing, analytical development, and nonclinical studies required before the candidate can enter IND/CTA-enabling studies.

The BiTAC platform is designed to improve the selectivity of T-cell engagers, potentially reducing toxicity associated with conventional approaches. By leveraging ATUM's expertise, VERAXA aims to accelerate the development of its lead oncology candidate toward clinical testing. The company recently expanded its research facilities in Heidelberg, Germany, to increase laboratory capacity as multiple oncology programs advance.

According to VERAXA, the selection of ATUM was based on its proven track record in cell line engineering. The Leap-In Transposase technology enables efficient and stable integration of genetic material, which is critical for producing consistent and high-yield cell lines for therapeutic protein production. This development milestone is essential for generating the material needed for toxicology studies and early-phase clinical trials.

VERAXA's lead BiTAC-TCE program targets a solid tumor indication, though the company has not disclosed the specific antigen. The broader BiTAC platform is designed to engage T cells more selectively, aiming to minimize off-target effects that have plagued earlier generations of T-cell engagers. The company believes this approach could lead to better therapeutic windows and improved patient outcomes.

The announcement comes amid growing interest in T-cell engagers as a class of immunotherapies. Several companies are developing bispecific antibodies that redirect T cells to cancer cells, but challenges with cytokine release syndrome and neurotoxicity remain. VERAXA's platform attempts to address these issues through a proprietary design that enhances tumor selectivity.

For investors, the partnership with ATUM is a tangible sign of progress as VERAXA moves its pipeline toward the clinic. The company's newsroom at https://ibn.fm/VRXA provides updates on its programs. VERAXA is listed on Nasdaq under the ticker VRXA and continues to develop its pipeline of novel cancer therapies.